Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347092 | 0.83 | NPC1 (0.47) | GAANPC1RAB9AKMT2A | |
| SCHEMBL10192549 | 0.81 | HTT (0.50) | EPHX1GAANPC1RAB9AKMT2A | |
| SCHEMBL3333820 | 0.79 | MAPT (0.46) | NPC1RAB9AKMT2A | |
| SCHEMBL8586120 | 0.78 | NAMPT (0.66) | EPHX1EPHX2TRPV1ENPP3ENPP1 | |
| SCHEMBL14108403 | 0.78 | MLLT1 (0.47) | NPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL28847292 | 0.77 | MLLT1 (0.46) | NPC1RAB9AKMT2A | |
| SCHEMBL3327579 | 0.76 | PTPN2 (0.51) | GAANPC1RAB9A | |
| SCHEMBL3367312 | 0.76 | NPC1 (0.43) | GAANPC1RAB9AKMT2A | |
| SCHEMBL3331408 | 0.74 | GNRHR (0.41) | — | |
| SCHEMBL3327972 | 0.74 | GNRHR (0.42) | GAANPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | EPHX1 3396/4885EPHX2 2057/4885TRPV1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.